2nd Humira Biosimilar Seen as Effective and Safe in Phase 3 Trial in China
News
HS016, a biosimilar candidate of Humira (adalimumab), was seen to have equivalent safety and effectiveness at treating adults with active ankylosing spondylitis (AS) in a Phase 3 trial in China. Researchers ... Read more